Allergies represent one of the most common chronic health conditions affecting individuals across all age groups worldwide. For those seeking reliable and non-drowsy relief from allergic symptoms, Allegra, known generically as fexofenadine, has established itself as a leading antihistamine medication. This comprehensive guide provides an in-depth exploration of Allegra, covering its pharmacological properties, clinical applications, proper usage guidelines, potential side effects, and important considerations for patients. Whether you are a long-time user of this medication or considering it for the first time, this article offers detailed information to support informed decision-making about your allergy treatment options.
What is allegra?
Allegra is the brand name for fexofenadine hydrochloride, a second-generation antihistamine that is widely used for the treatment of seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (chronic hives of unknown cause). Developed as a successor to earlier antihistamines, fexofenadine was designed to provide potent antihistamine activity with minimal sedative effects and a low potential for drug interactions. The medication is available over the counter in tablet, orally disintegrating tablet, and oral suspension forms, with strengths of 30 milligrams, 60 milligrams, 180 milligrams, and 30 milligrams per 5 milliliters depending on the formulation. Allegra is unique among second-generation antihistamines in that it is a zwitterionic compound, meaning it carries both positive and negative charges at physiological pH, which contributes to its limited penetration into the central nervous system and its excellent safety profile.
How allegra works in the body
The mechanism of action of Allegra is based on its selective antagonism of peripheral H1 histamine receptors. When the body encounters an allergen, the immune system triggers a cascade of events that ultimately leads to the release of histamine from mast cells and basophils. Histamine then binds to H1 receptors located on the surface of various cells throughout the body, including those in the respiratory tract, blood vessels, and skin. This binding activates signaling pathways that produce the characteristic symptoms of an allergic reaction, including vasodilation (widening of blood vessels), increased vascular permeability (leakage of fluid into tissues), smooth muscle contraction in the airways, and stimulation of sensory nerve endings that cause itching and sneezing.
Fexofenadine binds to H1 receptors with high affinity and selectivity, effectively blocking histamine from attaching to these receptors and thereby preventing the development of allergic symptoms. The specificity of fexofenadine for peripheral H1 receptors is particularly important because it minimizes the medication’s effects on the central nervous system. Unlike first-generation antihistamines that readily cross the blood-brain barrier and cause significant sedation, fexofenadine is actively transported out of the brain by P-glycoprotein, an efflux transporter located in the blood-brain barrier. This active removal mechanism ensures that fexofenadine concentrations in the brain remain very low, preserving cognitive function and alertness. The medication reaches peak plasma concentrations approximately one to three hours after oral administration and has a terminal elimination half-life of approximately 14.4 hours, supporting once-daily or twice-daily dosing depending on the formulation and indication.
Primary uses of allegra
Seasonal allergic rhinitis
Seasonal allergic rhinitis affects an estimated 10 to 30 percent of adults and up to 40 percent of children worldwide. The condition is triggered by airborne allergens such as tree, grass, and weed pollens that are present at specific times of the year. Symptoms include sneezing, rhinorrhea (runny nose), nasal congestion, nasal itching, and postnasal drip, and ocular symptoms such as itchy, watery, red, and swollen eyes. Allegra has been studied for the treatment of seasonal allergic rhinitis, with multiple randomized, double-blind, placebo-controlled trials confirming its efficacy in reducing both nasal and ocular symptoms. The 180-milligram once-daily dose is approved for this indication in adults and children aged 12 years and older, while children aged 6 to 11 years may take 30 milligrams twice daily. Clinical studies have demonstrated that Allegra provides significant symptom relief within one to three hours of administration, with effects lasting for the full 24-hour dosing interval.
Chronic idiopathic urticaria
Chronic idiopathic urticaria, also known as chronic spontaneous urticaria, is a condition characterized by the recurrent appearance of hives (wheals) and angioedema (swelling of the deeper layers of the skin) for six weeks or longer without an identifiable cause. This condition can impair quality of life, causing intense itching, sleep disturbance, and psychological distress. Allegra is approved for the treatment of chronic idiopathic urticaria in adults and children aged six months and older. The medication reduces the number, size, and duration of hives, and the severity of associated itching. Clinical studies have shown that fexofenadine is effective in reducing the symptoms of chronic urticaria, with improvements observed within the first few days of treatment. The recommended dose for this indication is 180 milligrams once daily for adults and children aged 12 years and older, with lower doses available for younger children.
Other allergic conditions
While Allegra is primarily indicated for allergic rhinitis and chronic urticaria, it may also be used off-label for other allergic conditions. Some healthcare providers prescribe fexofenadine for acute urticaria (hives lasting less than six weeks), allergic conjunctivitis (eye allergies), and atopic dermatitis (eczema), particularly when itching is a prominent symptom. The medication may also be used as part of a comprehensive treatment plan for patients with multiple allergic conditions. However, patients should be aware that the evidence supporting these off-label uses is less robust than for the approved indications, and they should discuss the potential risks and benefits with their healthcare provider before using Allegra for unapproved purposes.
Dosage forms and strengths
Allegra is available in several different formulations to accommodate the needs of various patient populations. The standard tablet formulation is available in strengths of 30 milligrams, 60 milligrams, 180 milligrams, and 180 milligrams for the over-the-counter version. The 60-milligram tablet is typically taken twice daily for the treatment of seasonal allergic rhinitis in adults, while the 180-milligram tablet is taken once daily for both allergic rhinitis and chronic urticaria. Orally disintegrating tablets, which are available in a 30-milligram strength, dissolve rapidly on the tongue without the need for water, making them convenient for use at work, school, or while traveling. The oral suspension formulation contains 30 milligrams of fexofenadine per 5 milliliters and is particularly useful for children and older adults who have difficulty swallowing tablets. Also, Allegra is available in combination products that contain pseudoephedrine, a decongestant, for patients who experience significant nasal congestion along with their other allergy symptoms.
Recommended dosage guidelines
Adult dosing
For adults and children aged 12 years and older with seasonal allergic rhinitis, the recommended dose of Allegra is 60 milligrams twice daily or 180 milligrams once daily. For chronic idiopathic urticaria in the same age group, the recommended dose is 180 milligrams once daily. The medication should be taken with water and can be taken with or without food. However, patients should be aware that consuming fruit juices such as apple, orange, or grapefruit juice within close proximity to taking Allegra can reduce the absorption of fexofenadine, potentially decreasing its effectiveness. It is recommended that Allegra be taken with water only and that fruit juices be avoided for at least one to two hours before and after taking the medication.
Pediatric dosing
For children aged 6 to 11 years with seasonal allergic rhinitis, the recommended dose of Allegra is 30 milligrams twice daily. For children aged 2 to 11 years with chronic idiopathic urticaria, the recommended dose is 15 milligrams twice daily (for children aged 2 to 5 years the dose is typically 15 milligrams twice daily, which requires the oral suspension formulation). Children aged 6 months to 2 years may be prescribed Allegra for urticaria at a dose of 15 milligrams once or twice daily, depending on the healthcare provider’s recommendation. Pediatric dosing should be carefully calculated based on the child’s weight and age, and parents should use the measuring device provided with the medication rather than household spoons to ensure accurate dosing. Children with reduced kidney function may require dose adjustment.
Geriatric dosing
Older adults may be more sensitive to the effects of antihistamines and may experience side effects such as dizziness, dry mouth, or urinary retention more frequently than younger patients. While the standard adult dose of Allegra is generally appropriate for healthy older adults, those with reduced kidney function may require dose adjustment. Fexofenadine is primarily excreted unchanged in the urine, and patients with a creatinine clearance of less than 30 milliliters per minute should start with a lower dose of 60 milligrams once daily. Older adults taking Allegra should be monitored for potential adverse effects, particularly those who are taking multiple medications or who have preexisting medical conditions that could increase their risk of complications.
Patients with renal or hepatic impairment
As mentioned above, fexofenadine is primarily eliminated through the kidneys. Patients with mild to moderate renal impairment may not require dose adjustment, but those with severe renal impairment (creatinine clearance less than 30 milliliters per minute) should receive a reduced dose. For adults with severe renal impairment, the recommended starting dose is 60 milligrams once daily. The effects of hepatic impairment on fexofenadine pharmacokinetics have not been studied, but given that the medication undergoes minimal hepatic metabolism, significant dose adjustment is likely not necessary for patients with liver disease. However, patients with any significant medical condition should consult their healthcare provider before starting Allegra to ensure that the medication is appropriate for their specific situation.
Potential side effects
Common side effects
Allegra is generally very well tolerated, with a side effect profile that is among the most favorable of all antihistamines. In clinical trials, the most commonly reported side effects with fexofenadine were similar to those reported with placebo, reflecting medication’s excellent tolerability. Headache was reported by approximately 10 percent of patients taking fexofenadine compared to approximately 8 percent taking placebo. Upper respiratory tract infection, back pain, and dysmenorrhea (painful menstruation) were also reported at rates similar to placebo. Drowsiness, which is a common concern with antihistamines, occurred at a rate of approximately 1 to 3 percent in clinical trials, which is comparable to the rate seen with placebo. This minimal sedative effect makes Allegra an excellent choice for individuals who need to remain alert and focused throughout the day.
Less common side effects
Less common side effects of Allegra include nausea, dyspepsia (indigestion), dizziness, fatigue, and insomnia. These side effects are typically mild and transient, often resolving on their own without the need for medical intervention. Dry mouth, which is a common side effect of many antihistamines, has been reported less frequently with fexofenadine than with other second-generation antihistamines such as cetirizine. Dermatological reactions including rash, urticaria, and pruritus (itching) have been reported in rare cases, although it can sometimes be difficult to distinguish whether these reactions are caused by the medication or by the underlying allergic condition being treated. Hypersensitivity reactions, including angioedema, chest tightness, dyspnea (difficulty breathing), flushing, and anaphylaxis, have been reported very rarely and require immediate medical attention.
Serious adverse reactions
Serious adverse reactions to Allegra are extremely rare. The medication has a wide therapeutic index, meaning that even doses higher than those recommended are unlikely to cause serious harm. In postmarketing surveillance, rare cases of hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Cardiovascular effects such as palpitations, tachycardia, and atrial fibrillation have been reported in isolated cases, although a causal relationship with fexofenadine has not been firmly established. Unlike some other antihistamines, fexofenadine has not been associated with QT interval prolongation, a cardiac conduction abnormality that can predispose patients to serious arrhythmias. This favorable cardiac safety profile makes Allegra a preferred antihistamine for patients with preexisting heart conditions or those taking medications that can affect cardiac conduction.
Drug interactions
Allegra has a low potential for drug interactions compared to many other medications, which is one of its key advantages. Unlike loratadine, which is metabolized by the cytochrome P450 enzyme system and can interact with medications that affect these enzymes, fexofenadine is not metabolized by the liver and does not inhibit or induce cytochrome P450 enzymes. This means that Allegra does not interact with the most medications that are metabolized by this system, including many commonly prescribed drugs for conditions such as high blood pressure, diabetes, high cholesterol, and depression.
The most clinically significant interaction with Allegra involves the concomitant administration of aluminum- or magnesium-containing antacids. These antacids can bind to fexofenadine in the gastrointestinal tract and reduce its absorption by approximately 40 percent. Patients taking antacids should space them at least two hours apart from Allegra to minimize this interaction. As previously mentioned, fruit juices such as apple, orange, and grapefruit juice can also reduce the absorption of fexofenadine by inhibiting organic anion transporting polypeptides (OATPs) in the gastrointestinal tract. Patients should take Allegra with water only and avoid fruit juices for at least one to two hours before and after taking the medication. Erythromycin and ketoconazole can increase fexofenadine plasma concentrations by approximately 60 to 70 percent, but this interaction is not considered clinically significant because fexofenadine has a wide therapeutic index and no dose adjustment is required.
Precautions and contraindications
Who should not take allegra
Allegra is contraindicated in patients with known hypersensitivity to fexofenadine or any of the inactive ingredients in the formulation. Patients who have experienced an allergic reaction to fexofenadine in the past should not take Allegra or any other medication containing fexofenadine. Patients with severe renal impairment should use Allegra with caution and may require dose adjustment as described in the dosing section. The medication has not been studied in patients with severe hepatic impairment, although significant effects are not expected given minimal hepatic metabolism of fexofenadine. Patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should be aware that some formulations of Allegra contain lactose and may not be appropriate for their use.
Pregnancy and breastfeeding
The safety of Allegra during pregnancy has been evaluated in animal studies and limited human data. Animal studies have not demonstrated teratogenic effects at doses higher than those used in humans. The medication is classified as Pregnancy Category C by the FDA, meaning that animal studies have shown an adverse effect on the fetus but adequate human studies are not available, and the potential benefits may warrant use of the medication in pregnant women despite potential risks. Pregnant women should consult their healthcare provider before taking Allegra and should use the medication only if clearly needed. Fexofenadine is excreted in breast milk in small amounts, and while it is compatible with breastfeeding, nursing mothers should discuss the risks and benefits with their healthcare provider. The American Academy of Pediatrics considers fexofenadine to be compatible with breastfeeding.
Use in children
Allegra is approved for use in children as young as six months of age for the treatment of chronic idiopathic urticaria and from two years of age for the treatment of allergic rhinitis. Parents and caregivers should ensure that the appropriate formulation and dose are used for the child’s age and weight. The oral suspension formulation is often the most convenient option for young children, while older children may prefer the orally disintegrating tablets or standard tablets. Children should be monitored for side effects, although the incidence of adverse effects in pediatric clinical trials was similar to that in adults. It is important to keep Allegra and all medications out of reach of children to prevent accidental overdose.
Use in older adults
As with all medications, older adults may be more susceptible to the side effects of Allegra. While fexofenadine has a particularly favorable safety profile in this population due to its minimal sedative and anticholinergic effects, older adults with reduced kidney function may be at increased risk of adverse effects due to reduced drug clearance. Healthcare providers should carefully evaluate kidney function in older adult patients before prescribing Allegra and adjust the dose if necessary. Older adults should also be advised to maintain adequate hydration while taking Allegra, as dehydration can increase the risk of side effects.
Comparative effectiveness
Allegra vs. First-generation antihistamines
First-generation antihistamines such as diphenhydramine (Benadryl), chlorpheniramine (Chlor-Trimeton), and hydroxyzine (Atarax) have been available for decades and are effective at relieving allergy symptoms. However, these medications are associated with significant sedation, cognitive impairment, and anticholinergic effects due to their ability to freely cross the blood-brain barrier. Studies have shown that diphenhydramine can impair driving performance as much as or more than alcohol intoxication. In contrast, Allegra provides comparable or superior efficacy with virtually no sedation or cognitive impairment. Multiple studies have demonstrated that fexofenadine does not impair psychomotor performance, driving ability, or cognitive function, even at doses higher than those recommended. This makes Allegra a clearly superior choice for individuals who need to drive, operate machinery, or perform tasks requiring mental alertness.
Allegra vs. Other second-generation antihistamines
Among second-generation antihistamines, Allegra is often considered the least sedating option. While cetirizine (Zyrtec) is slightly more effective for some patients, it causes more sedation, with approximately 10 to 15 percent of patients experiencing drowsiness compared to 1 to 3 percent with fexofenadine. Loratadine (Claritin, Alavert) has a similar non-sedating profile to fexofenadine but may be less effective for some patients and has a slower onset of action. Levocetirizine (Xyzal) and desloratadine (Clarinex) are newer second-generation antihistamines with similar efficacy and safety profiles to fexofenadine. The choice between these medications often depends on individual patient response, as some patients may respond better to one medication than another. Patients who do not achieve adequate symptom control with one second-generation antihistamine may benefit from trying another within the same class.
Allegra vs. Intranasal corticosteroids
Intranasal corticosteroids such as fluticasone propionate (Flonase), triamcinolone (Nasacort), and mometasone furoate (Nasonex) are considered the gold standard for the treatment of allergic rhinitis, particularly for nasal congestion. These medications work by reducing inflammation in the nasal passages and are generally more effective than oral antihistamines for overall symptom control, especially for nasal congestion. However, intranasal corticosteroids have a slower onset of action, typically requiring several days to reach full effectiveness, and some patients find them less convenient to use than oral medications. Many patients benefit from combining an intranasal corticosteroid with an oral antihistamine such as Allegra for optimal symptom control. The choice between these medication classes depends on the patient’s predominant symptoms, preferences, and response to treatment. Patients with primarily ocular symptoms may prefer an oral antihistamine, while those with significant nasal congestion may benefit more from an intranasal corticosteroid.
Special considerations for allergy management
Environmental control measures
While Allegra is highly effective at relieving allergy symptoms, comprehensive allergy management should include measures to reduce exposure to triggering allergens. For patients with pollen allergies, monitoring local pollen counts and staying indoors during peak pollen times, typically early morning and late afternoon, can help reduce symptom severity. Keeping windows closed during allergy season and using air conditioning with HEPA filters can reduce indoor pollen levels. Regular showering and changing clothes after spending time outdoors can also help remove pollen from the skin and hair. For patients with dust mite allergies, encasing mattresses and pillows in allergen-proof covers, washing bedding in hot water weekly, and reducing indoor humidity to below 50 percent can be effective. For pet allergies, keeping pets out of bedrooms, using HEPA air purifiers, and bathing pets regularly can help reduce allergen levels. These environmental control measures, combined with appropriate medication use, provide the best approach to allergy management.
When to see a specialist
While many patients can manage their allergies with over-the-counter medications such as Allegra and basic environmental control measures, some patients may benefit from referral to an allergist or immunologist. Indications for specialist referral include inadequate symptom control despite appropriate medication use, persistent symptoms that interfere with daily activities or quality of life, recurrent sinusitis or otitis media (ear infections), suspected asthma, and consideration of immunotherapy. An allergist can perform skin testing or blood testing to identify specific allergen triggers and develop a comprehensive treatment plan. For patients with severe allergies or those who do not respond well to medications, allergen immunotherapy can provide long-term relief by modifying the immune response to specific allergens.
Proper storage and handling
Allegra should be stored at room temperature, between 20 and 25 degrees Celsius (68 to 77 degrees Fahrenheit), in a dry location away from heat, moisture, and direct light. The medication should be kept in its original container with the lid tightly closed. Orally disintegrating tablets should be kept in their original blister packs until just before use, as they are sensitive to moisture. The oral suspension formulation should not be frozen and should be used within the time specified on the bottle after opening. Allegra should not be stored in the bathroom or kitchen, where temperature and humidity fluctuations can affect its stability. The medication should be kept out of reach of children and pets. Expired Allegra should be disposed of properly through medication take-back programs or by following the disposal instructions on the packaging.
Frequently asked questions
How quickly does allegra work?
Allegra typically begins to work within one to three hours after oral administration, with peak effectiveness reached at approximately four to six hours. The orally disintegrating tablet formulation may provide slightly faster absorption. For the treatment of chronic urticaria, patients may notice improvement within the first few days of treatment, although maximum benefit may take one to two weeks.
Can i take allegra every day?
Yes, Allegra is safe for daily use during allergy season or year-round for patients with perennial allergies or chronic urticaria. The medication is designed for regular use and maintains its effectiveness over time without the development of tolerance. Patients who require daily treatment should take Allegra at approximately the same time each day to maintain consistent blood levels.
What is the difference between allegra 60 mg and 180 mg?
The 60-milligram strength of Allegra is typically taken twice daily for seasonal allergic rhinitis, while the 180-milligram strength is taken once daily for both seasonal allergic rhinitis and chronic idiopathic urticaria. The total daily dose of fexofenadine is the same with both regimens, and clinical studies have shown that both dosing schedules provide equivalent efficacy. The choice between the two regimens depends on patient preference and convenience.
Can allegra be taken with other allergy medications?
Allegra should not be taken with other oral antihistamines, as this can increase the risk of side effects without providing additional benefit. However, Allegra can be safely combined with intranasal corticosteroids, leukotriene receptor antagonists (such as montelukast), and mast cell stabilizers (such as cromolyn sodium) for more comprehensive symptom control. Patients should consult their healthcare provider before combining Allegra with any other medication.
Does allegra cause weight gain?
Weight gain is not a known side effect of Allegra. Unlike some first-generation antihistamines and certain other second-generation antihistamines, fexofenadine has not been associated with increased appetite or weight gain in clinical studies. Patients who experience unexplained weight gain while taking Allegra should consult their healthcare provider to investigate other potential causes.
Can allegra be taken with high blood pressure medication?
Allegra is generally safe to take with most high blood pressure medications. Unlike decongestants, which can raise blood pressure, fexofenadine has no significant cardiovascular effects at recommended doses. However, patients taking combination products that contain fexofenadine with pseudoephedrine should be cautious, as the decongestant component can increase blood pressure and heart rate.
Is allegra safe for long-term use?
Yes, Allegra is considered safe for long-term use. Clinical studies have evaluated fexofenadine for periods of up to 12 months with no significant safety concerns. The medication does not accumulate in the body with long-term use, and there is no evidence of tolerance or dependence developing with continued treatment. However, patients who require long-term antihistamine therapy should be monitored periodically by their healthcare provider.
Can i drink alcohol while taking allegra?
Unlike first-generation antihistamines, Allegra does not potentiate the effects of alcohol. Studies have shown that fexofenadine does not increase alcohol-induced impairment of cognitive function or psychomotor performance. However, moderate alcohol consumption is always recommended when taking any medication, and patients should be aware of their individual response to the combination.
Can allegra be crushed or split?
Allegra tablets should not be crushed or split unless specifically instructed by a healthcare provider. The tablets are designed to be swallowed whole with water. Patients who have difficulty swallowing tablets may benefit from the orally disintegrating tablet formulation or the oral suspension formulation, which are specifically designed for easy administration.
What should i do if i miss a dose?
If you miss a dose of Allegra, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double up on doses to make up for a missed dose, as this increases the risk of side effects without providing additional benefit.
Clinical studies and efficacy data
The efficacy and safety of fexofenadine have been established through an extensive clinical development program involving thousands of patients. In an important phase III study published in the Journal of Allergy and Clinical Immunology, fexofenadine 180 milligrams once daily reduced total symptom scores in patients with seasonal allergic rhinitis compared to placebo, with improvements in sneezing, rhinorrhea, nasal itching, nasal congestion, and itchy eyes. The onset of action was observed within one hour of the first dose, and the effect was maintained throughout the 24-hour dosing interval. A meta-analysis of randomized controlled trials confirmed these findings, demonstrating that fexofenadine is consistently superior to placebo for the treatment of allergic rhinitis and comparable in efficacy to other second-generation antihistamines.
For chronic idiopathic urticaria, clinical studies have demonstrated that fexofenadine reduces the number of hives, the size of individual hives, and the severity of itching compared to placebo. A dose-ranging study found that the 180-milligram dose provided the optimal balance of efficacy and tolerability. Quality of life studies have shown that Allegra improves sleep quality, daily functioning, and emotional well-being in patients with chronic urticaria. Studies specifically evaluating the central nervous system effects of fexofenadine have consistently shown no significant sedation, cognitive impairment, or psychomotor slowing, even at doses up to 360 milligrams. Objective measures of driving performance have confirmed that fexofenadine does not impair driving ability, making it one of the safest antihistamines for use by individuals who drive regularly.